Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGA-FORTE
- Development stage
- Unknown
- Lead developer
- Nidus Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
AGA-FORTE is an oral combination pharmaceutical product developed and marketed by Nidus Pharma, primarily indicated for the treatment of androgenetic alopecia (male pattern hair loss). The formulation typically combines finasteride, a type II 5-alpha reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone (DHT), with biotin (Vitamin B7) and a complex of essential minerals (such as zinc, selenium, and copper) and amino acids. By lowering systemic and scalp DHT levels while providing nutritional support for hair follicle health and structural integrity, AGA-FORTE aims to arrest hair thinning and promote the revitalization of miniaturized hair follicles. It is sold as a specialty dermatology product in the Indian market.
- Brand names
- AGA-FORTE
- Other names
- finasteride + biotin + mineralsAGA FORTE
02
Targets
SRD5A2 (Steroid 5-alpha-reductase type II)
Beyond the preview
Go deeper on AGA-FORTE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGA-FORTE.